ABIO (ARCA Biopharma, Inc.) Earnings per share for the trailing year

ARCA Bio (ABIO) - corporate logo

ARCA Biopharma's experienced management is focused on scientific achievements, as evidenced by the trajectory of the current EPS YoY TTM growth rate on the GURU.Markets chart, where the value remains at 46.90. The strategy relies on the success of Gencaro trials and a personalized approach, while the work of R&D laboratories and batch production rates strictly align with the company's internal plans.

ARCA Biopharma Inc (ABIO) - Net earnings per share (EPS TTM) from 02/11/2024 to 02/20/2024

ABIO (ARCA Biopharma): analytical breakdowns and indicator data

- current quotes and average value forecast:
- business market valuation indicators:
Fundamental company valuation:ARCA Biopharma Inc ABIO
Core merchandise of ARCA Bio

This indicator measures the rate of change in net income per share over twelve months, reflecting capital sensitivity to external shocks and liquidity. It allows for an assessment of the issuer's fundamental stability under tight monetary policy. For ARCA Biopharma (ABIO), which has no revenue, the 46.90 value confirms a stage of systematic reserve depletion. By analyzing the annual change in net income per share over a rolling period, an investor can see the actual burn rate of the cash position.